SYRA HEALTH CORP. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.48 USD | -30.84% |
|
+26.67% | +49.65% |
| 02:17pm | Earnings Flash (SYRA) SYRA HEALTH Reports Q1 Revenue $1.8M | MT |
| 02:02pm | SYRA HEALTH CORP SHARES DOWN 9.3% PREMARKET AFTER Q1 RESULTS… | RE |
Valuation
| Fiscal Period: December | 2023 | 2024 |
|---|---|---|
| Capitalization 1 | 14.14 | 30.18 |
| Enterprise Value (EV) 1 | 14.14 | 30.18 |
| P/E ratio | - | - |
| Yield | - | - |
| Capitalization / Revenue | 2.56 x | 3 x |
| EV / Revenue | 2.56 x | 3 x |
| EV / EBITDA | - | - |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Price to Book | - | - |
| Nbr of stocks (in thousands) | 13,922 | 14,102 |
| Reference price 2 | 1.016 | 2.140 |
| Announcement Date | 3/25/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net sales 1 | - | 5.515 | 10.07 |
| EBITDA | - | - | - |
| EBIT 1 | - | -2.888 | -3.327 |
| Operating Margin | - | -52.36% | -33.04% |
| Earnings before Tax (EBT) | - | - | - |
| Net income | -2.118 | - | - |
| Net margin | - | - | - |
| EPS | -0.5800 | - | - |
| Free Cash Flow | - | - | - |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 5/4/23 | 3/25/24 | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|
| Net sales 1 | 1.766 | 1.402 | 2.771 | 2.846 | 3.049 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -0.9862 | -1.06 | -0.7478 | -0.7458 | -0.7734 |
| Operating Margin | -55.83% | -75.59% | -26.99% | -26.2% | -25.37% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/25/24 | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Debt | - | - | - |
| Net Cash position | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets | - | - | - |
| Book Value Per Share | - | - | - |
| Cash Flow per Share | - | - | - |
| Capex | - | - | - |
| Capex / Sales | - | - | - |
| Announcement Date | 5/4/23 | 3/25/24 | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +110.69% | 30.18M | |
| -18.39% | 16.61B | |
| +4.50% | 12.48B | |
| +4.48% | 11.7B | |
| +1.79% | 10.07B | |
| -4.37% | 7.7B | |
| +21.11% | 7.3B | |
| +3.46% | 6.56B | |
| +47.50% | 4.55B | |
| -4.50% | 4.17B |
- Stock Market
- Equities
- SYRA Stock
- Financials Syra Health Corp.